These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16640330)

  • 1. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
    Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
    J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
    Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
    Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
    Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
    Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
    Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study.
    Salam NK; Huang TH; Kota BP; Kim MS; Li Y; Hibbs DE
    Chem Biol Drug Des; 2008 Jan; 71(1):57-70. PubMed ID: 18086153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
    Ji CG; Zhang JZ
    J Am Chem Soc; 2008 Dec; 130(50):17129-33. PubMed ID: 19007119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
    Ahn JH; Shin MS; Jung SH; Kang SK; Kim KR; Rhee SD; Jung WH; Yang SD; Kim SJ; Woo JR; Lee JH; Cheon HG; Kim SS
    J Med Chem; 2006 Jul; 49(15):4781-4. PubMed ID: 16854085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A; Godio C; Laghezza A; Mitro N; Fracchiolla G; Tortorella V; Lavecchia A; Novellino E; Fruchart JC; Staels B; Crestani M; Loiodice F
    J Med Chem; 2005 Aug; 48(17):5509-19. PubMed ID: 16107150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
    Peng YH; Coumar MS; Leou JS; Wu JS; Shiao HY; Lin CH; Lin WH; Lien TW; Chen X; Hsu JT; Chao YS; Huang CF; Lyu PC; Hsieh HP; Wu SY
    ChemMedChem; 2010 Oct; 5(10):1707-16. PubMed ID: 20734309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists.
    Liu Q; Zhang YY; Lu HL; Li QY; Zhou CH; Wang MW
    Acta Pharmacol Sin; 2007 Dec; 28(12):2033-9. PubMed ID: 18031620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.
    Mahindroo N; Huang CF; Peng YH; Wang CC; Liao CC; Lien TW; Chittimalla SK; Huang WJ; Chai CH; Prakash E; Chen CP; Hsu TA; Peng CH; Lu IL; Lee LH; Chang YW; Chen WC; Chou YC; Chen CT; Goparaju CM; Chen YS; Lan SJ; Yu MC; Chen X; Chao YS; Wu SY; Hsieh HP
    J Med Chem; 2005 Dec; 48(26):8194-208. PubMed ID: 16366601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
    Dong X; Zhang Z; Wen R; Shen J; Shen X; Jiang H
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5913-6. PubMed ID: 17010604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational screening of phthalate monoesters for binding to PPARgamma.
    Kaya T; Mohr SC; Waxman DJ; Vajda S
    Chem Res Toxicol; 2006 Aug; 19(8):999-1009. PubMed ID: 16918238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
    Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.
    Shiraki T; Kodama TS; Jingami H; Kamiya N
    Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.